NeuroScientific Biopharmaceuticals Limited (NSB.AX)
NeuroScientific Biopharmaceuticals Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Perth, WA, AU. The stock last traded at $0.06, down 7.81% on the session, giving a market capitalisation of $23.0M. Its beta of 1.12 implies it has historically moved more than the broad market.
Established in 2002 and headquartered in Cottesloe, Australia, NeuroScientific Biopharmaceuticals Limited specializes in the development of medical therapies for neurodegenerative conditions. The company conducts extensive preclinical and clinical research utilizing its proprietary technological platforms to advance these treatments. Its primary pharmaceutical compound, EmtinB, is being developed as a potential therapeutic agent for diseases including neurodegenerative dementia, Alzheimer's disease, and various degenerative disorders affecting the optic nerve.
NeuroScientific Biopharmaceuticals Limited is most often compared with the following Healthcare names: